Does Mounjaro Affect Pregnancy — and What Should You Do If You're Pregnant?

What the official guidance and animal data actually show

The Mounjaro Summary of Product Characteristics, published on the electronic Medicines Compendium, states that tirzepatide should not be used in pregnancy. That position is not precautionary hedging — it is grounded in the available data. Animal reproductive studies found adverse effects on embryo-foetal development at exposures within the range seen in treated humans. Weight loss itself, as well as caloric restriction driven by appetite suppression, carries independent risks during pregnancy, including restricted foetal growth. The full picture of how tirzepatide may affect a developing pregnancy is more complex than a single trial figure can capture, precisely because the human controlled studies have not been done. The NHS tirzepatide medicines page confirms the not-recommended status for pregnant women, women planning a pregnancy, and those who are breastfeeding. The NHS's guidance on tirzepatide is the most practical starting point for patients trying to understand what this means day to day.

The honest answer to whether Mounjaro can affect pregnancy is: we do not know with certainty in humans, and the preclinical signals are sufficient for regulators to advise against any exposure. That is the scientific position as of mid-2026.

Why oral contraception and Mounjaro interact, and what to do about it

One of the more practical concerns on this topic is how tirzepatide interacts with hormonal contraception. Because Mounjaro slows gastric emptying, the absorption of oral contraceptives taken at the same time can be reduced. The MHRA and NHS England both advise that women using the combined or progestogen-only pill should use a non-oral method of contraception (condoms, for example) for the first four weeks of starting treatment and for four weeks after every dose increase. Whether Mounjaro itself has any contraceptive effect is a separate question; it does not. The concern is the opposite: that the pill becomes less reliable, raising the risk of an unintended pregnancy. NHS England's weight-management injections guidance covers this in detail. Transdermal methods (patches, implants, the coil) are not affected by gastric motility and do not carry this risk. If you start a new pen on a Monday morning and you rely on the pill, the four-week window applies from that same day.

This is a question our prescribers hear regularly. For women with PCOS, where fertility can be unpredictable, the interaction deserves particular attention, weight loss on tirzepatide has in some cases restored ovulation in women who previously assumed they were unlikely to conceive.

If you find out you are pregnant while taking Mounjaro

Stop taking Mounjaro. That is the clear, consistent clinical advice. Then contact your GP or midwife as soon as possible, ideally the same day, or the next morning if you find out late in the evening. Tirzepatide has a half-life of approximately five days, meaning it clears the body over a period of weeks rather than hours; knowing when your last dose was will be useful information for your clinical team. You do not need to panic, but you do need to act quickly and honestly with your healthcare providers. What happens next for women who were on Mounjaro when they conceived depends on gestation, dose history, and individual clinical factors that only your team can assess. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk accepts reports of suspected side effects during pregnancy, and reporting helps build the evidence base for future patients. If you have questions about resuming treatment after pregnancy or breastfeeding, more on Mounjaro's licensed use for weight management is a useful reference once your clinical situation has settled.

Planning ahead: stopping Mounjaro before trying to conceive

If pregnancy is something you are planning rather than discovering unexpectedly, the guidance is to stop Mounjaro before you start trying. There is no officially specified wash-out period in the UK SmPC, but given the approximately five-day half-life and the principle of minimising any foetal exposure, most clinicians advise allowing sufficient time for the medicine to clear before conception. Discuss the specifics with your GP or a specialist rather than working from a generic timeline. Weight regain after stopping is a recognised clinical reality; having a plan for that period is part of responsible preparation. Thinking through the timing before stopping treatment is worth doing in advance rather than under pressure. For a broader view of your treatment options, including what a clinical assessment involves, our consultation page outlines the process. A prescriber review, not a search engine, is the right place to settle the specific question of when to stop and what support is available in the interim.